An observational study in Type B Aortic Dissection, Tevar and CFD, sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine. Completed at 3 sites in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-08-21.
Sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study proposes a retrospective analysis that systematically integrates multidimensional biomechanical and anatomical data to construct an early and accurate predictive model for adverse aortic remodeling following thoracic endovascular aortic repair (TEVAR) in patients with Type B aortic dissection (TBAD). Postoperative follow-up CTA images will be analyzed using vascular deformation mapping (VDM) technology, which enables quantitative assessment of regional aortic deformation and strain evolution through high-precision three-dimensional registration, thereby overcoming the limitations of conventional diameter-based measurements. Concurrently, patient-specific computational fluid dynamics (CFD) models will be reconstructed from preoperative CTA data to simulate the hemodynamic environment within the dissected aorta, extracting key parameters including wall shear stress, flow velocity, and pressure distribution to quantify the mechanical forces driving vascular remodeling. Furthermore, the anatomical characteristics of entry tears-including their number, spatial distribution, and size-will be systematically characterized. By integrating these three dimensions of indicators and employing multivariable regression and machine learning algorithms, independent risk factors significantly associated with adverse events such as false lumen aneurysmal expansion, aortic rupture, and recurrent dissection will be identified, ultimately establishing a comprehensive predictive model that combines sensitivity, objectivity, and clinical feasibility. The development of this model is expected to provide clinicians with quantitative decision support for early identification of high-risk patients, formulation of individualized surveillance strategies, and implementation of timely interventions, thereby substantially improving the long-term prognosis and quality of life for TBAD patients following TEVAR.
Inclusion Criteria: (1) Age between 18 and 85 years, male or non-pregnant female. (2) CTA-confirmed diagnosis of Type B aortic dissection, classified as acute uncomplicated dissection. (3) Underwent TEVAR (thoracic endovascular aortic repair) procedure. (4) At least one preoperative and three postoperative CTA examinations available, with imaging coverage extending cranially to include the brachiocephalic trunk, left common carotid artery, and the origin of the left subclavian artery, and caudally to cover the origins of the internal and external iliac arteries.
Exclusion Criteria: (1) Age \<18 or >85 years. (2) Traumatic or iatrogenic dissection, or isolated aortic aneurysm. (3) Chronic or complicated dissection. (4) Penetrating aortic ulcer (PAU) or intramural hematoma (IMH), as well as localized dissection. (5) Connective tissue disorders, such as Marfan syndrome. (6) Prior history of cardiac or aortic surgery. (7) Absence of signed surgical informed consent. (8) Insufficient CTA examinations or inadequate imaging coverage/quality. (9) Failure of image registration precluding completion of the VDM analysis workflow.
Second Affiliated Hospital, Zhejiang University, School of Medicine is the lead sponsor of 104 studies on the registry; 70 are open to participants now.
Counted across the registry records on this site, refreshed daily.
This study population comprises patients diagnosed with acute uncomplicated Type B aortic dissection who underwent thoracic endovascular aortic repair (TEVAR) at a single center. Eligible patients were aged 18 to 85 years, male or non-pregnant female, and had at least one preoperative and three postoperative CTA examinations with adequate imaging coverage from the brachiocephalic trunk to the iliac arteries. Patients with traumatic or iatrogenic dissection, chronic or complicated dissection, penetrating aortic ulcer (PAU), intramural hematoma (IMH), localized dissection, connective tissue disorders (e.g., Marfan syndrome), prior cardiac or aortic surgery, insufficient imaging quality, or failed image registration for VDM analysis were excluded. A total of 1000 patients were enrolled and followed for up to 5 years post-TEVAR to assess adverse aortic remodeling outcomes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
(1) Age between 18 and 85 years, male or non-pregnant female. (2) CTA-confirmed diagnosis of Type B aortic dissection, classified as acute uncomplicated dissection. (3) Underwent TEVAR (thoracic endovascular aortic repair) procedure. (4) At least one preoperative and three postoperative CTA examinations available, with imaging coverage extending cranially to include the brachiocephalic trunk, left common carotid artery, and the origin of the left subclavian artery, and caudally to cover the origins of the internal and external iliac arteries.
Exclusion Criteria:
(1) Age \<18 or >85 years. (2) Traumatic or iatrogenic dissection, or isolated aortic aneurysm. (3) Chronic or complicated dissection. (4) Penetrating aortic ulcer (PAU) or intramural hematoma (IMH), as well as localized dissection. (5) Connective tissue disorders, such as Marfan syndrome. (6) Prior history of cardiac or aortic surgery. (7) Absence of signed surgical . (8) Insufficient CTA examinations or inadequate imaging coverage/quality. (9) Failure of image registration precluding completion of the VDM analysis workflow.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TEVAR using commercially available stent-grafts via femoral access, covering the primary entry tear to promote false lumen thrombosis and aortic remodeling. This single-arm cohort includes acute uncomplicated TBAD patients treated with TEVAR, with adequate pre- and post-operative CTA imaging. Exclusions include connective tissue disorders, traumatic/iatrogenic dissection, PAU/IMH, prior aortic surgery, and insufficient imaging quality. The cohort is analyzed retrospectively using VDM, CFD, and tear morphology to predict adverse remodeling outcomes
Procedure: Thoracic Endovascular Aortic Repair
Thoracic endovascular aortic repair (TEVAR) with commercially available stent-graft devices, implanted via femoral arterial access under fluoroscopic guidance. The intervention involves covering the primary entry tear with a stent-graft to redirect blood flow into the true lumen.
Composite of Adverse Aortic Remodeling
A composite endpoint defined as the occurrence of any of the following events during follow-up: (1) aneurysmal dilation of the stented or distal aorta to ≥5.0 cm; (2) aneurysmal dilation rate ≥0.5 cm/year; (3) rupture or signs of imminent rupture; (4) visceral and/or lower limb malperfusion; (5) distal stent-induced new entry (d-SINE); (6) Type I, II, III, or R endoleak.
Time frame: Up to 5 years post-procedure
All-Cause Mortality
Death from any cause during follow-up.
Time frame: Up to 5 years post-procedure
Aortic-Related Mortality
Death related to progression of aortic dissection or complications following TEVAR during follow-up.
Time frame: Up to 5 years post-procedure
Aortic-Related Secondary Intervention Rate
Rate of secondary interventions related to progression of aortic dissection or complications from the initial TEVAR procedure. Indications for secondary intervention include: Type I/III endoleak, Type II endoleak with concomitant false lumen aneurysmal dilation, retrograde Type A dissection (RTAD), distal stent-induced new entry (d-SINE) causing pain or persistent false lumen perfusion, distal aneurysmal dilation, and left subclavian artery (LSA) steal syndrome due to LSA coverage during the initial intervention. Secondary intervention strategies include: endovascular approaches (repeat stent-graft implantation, branch artery stenting, chimney/periscope techniques, coil embolization) and open surgical approaches (artificial vascular graft replacement, supra-aortic or visceral branch artery bypass/transposition).
Time frame: Up to 5 years post-procedure
Visceral Artery Branch Lumen Loss Rate
Rate of visceral artery branch lumen loss during follow-up, assessed by serial CTA imaging.
Time frame: Up to 5 years post-procedure
False Lumen Thrombosis Status
Degree of false lumen thrombosis assessed by serial CTA imaging during follow-up. Thrombosis status is categorized based on the extent of thrombus formation within the false lumen.
Time frame: Up to 5 years post-procedure
Aortic-Related Adverse Events (AAEs) Rate
Rate of aortic-related adverse events (AAEs) during follow-up. AAEs are defined as a composite of: aortic-related death, major adverse cardiovascular events, stroke, acute renal insufficiency, rupture, spinal cord ischemia, mesenteric ischemia, lower limb ischemia, retrograde Type A dissection (RTAD), distal stent-induced new entry (d-SINE), stent-graft migration, stent-graft infection, and access site complications.
Time frame: Up to 5 years post-procedure
Plan to share: No
No publications or documents are linked to this record.
Ran from Jan 2020 to primary completion in Dec 2025, 71 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Second Affiliated Hospital, Zhejiang University, School of Medicine →